Alviggi Carlo, Revelli Alberto, Anserini Paola, Ranieri Antonio, Fedele Luigi, Strina Ida, Massobrio Marco, Ragni Nicola, De Placido Giuseppe
Department of Obstetrica/Gynecological Sciences and Reproductive Medicine, Federico II University, Napoli, Italy.
Reprod Biol Endocrinol. 2007 Dec 4;5:45. doi: 10.1186/1477-7827-5-45.
Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.) self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG preparation.
A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional s.c. or i.m. They started MOS with a standard hMG dose between 150-300 IU, depending upon patient's age, and underwent a standard IVF procedure.
No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups, respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%, respectively). Pain at injection site was reported only the i.m. group (13.9% of patients).
Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall safety.
多卵泡卵巢刺激(MOS)在体外受精(IVF)中被广泛应用,治疗的依从性深受所用药物的耐受性以及自我给药的便捷程度影响。这项前瞻性、对照、随机、平行组开放标签、多中心、III期等效性研究旨在比较皮下(s.c.)自我注射与传统肌肉注射新型高纯度人绝经期促性腺激素(hMG)制剂Merional的临床有效性(以获得的卵母细胞数量衡量)和耐受性。
共纳入168名接受IVF的正常促性腺激素水平女性。其中,160名采用促性腺激素释放激素(GnRH)激动剂长方案实现垂体抑制,并被随机分配接受Merional皮下或肌肉注射进行MOS治疗。她们根据患者年龄,以150 - 300国际单位(IU)的标准hMG剂量开始MOS治疗,并接受标准IVF程序。
两个研究亚组之间在收集的卵母细胞平均数量(主要终点)上未观察到统计学显著差异(皮下和肌肉注射亚组分别为7.46,标准差4.24和7.86,标准差4.28)。关于次要结局,亚组之间的妊娠率和临床妊娠率相当。两组不良事件发生率相似(分别为2.4%和3.7%)。仅在肌肉注射组报告了注射部位疼痛(13.9%的患者)。
在IVF中,Merional可通过皮下注射使用,在获取卵母细胞方面的有效性等同于肌肉注射,且局部耐受性更好。鉴于本研究样本量的局限性,皮下和肌肉注射途径似乎具有相同的总体安全性。